| Year |
Citation |
Score |
| 2023 |
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, ... ... Bowtell DD, et al. Author Correction: The evolutionary history of 2,658 cancers. Nature. PMID 36697833 DOI: 10.1038/s41586-022-05601-4 |
0.526 |
|
| 2020 |
Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, Allan P, Carey MS, Fernandez ML, Dawson A, Köbel M, Huntsman DG, Page CL, Mes-Masson AM, Provencher D, ... ... Bowtell D, et al. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. The Journal of Pathology. PMID 32901952 DOI: 10.1002/path.5545 |
0.407 |
|
| 2020 |
Hunter SM, Dall GV, Doyle MA, Lupat R, Li J, Allan P, Rowley SM, Bowtell D, Campbell IG, Gorringe KL. Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours. Bmc Research Notes. 13: 349. PMID 32698852 DOI: 10.1186/s13104-020-05194-z |
0.303 |
|
| 2020 |
Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo A, Hein A, Talhouk A, Osorio A, Hartkopf AD, Brooks-Wilson A, DeFazio A, ... ... Bowtell DD, et al. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer. PMID 32555365 DOI: 10.1038/S41416-020-0900-0 |
0.304 |
|
| 2020 |
Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, Traficante N, Group A, Brenton J, Goranova T, Hosking K, Piskorz A, van Oudenhove E, Doherty J, Harris HR, et al. Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics. PMID 32546565 DOI: 10.1136/Jmedgenet-2019-106739 |
0.3 |
|
| 2020 |
Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, ... ... Bowtell DD, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32473302 DOI: 10.1016/J.Annonc.2020.05.019 |
0.389 |
|
| 2020 |
Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, Vázquez-García I, ... ... Bowtell DD, et al. The evolutionary history of 2,658 cancers. Nature. 578: 122-128. PMID 32025013 DOI: 10.1038/S41586-019-1907-7 |
0.559 |
|
| 2020 |
Mileshkin LR, Posner A, Pattison A, Balachander S, Etemadmoghadam D, Fellowes A, Wong HL, Dow E, deFazio A, Gao B, Karapetis CS, Singh MS, Collins IM, Steer C, Warren MA, ... ... Bowtell D, et al. Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E15252 |
0.376 |
|
| 2020 |
Garsed D, Pandey A, Fereday S, Alsop K, Wouters M, Saner F, Kennedy C, Pearce C, Pike M, Ramus S, Kobel M, deFazio A, Goode E, Nelson B, Bowtell D. Abstract IA05: Molecular analysis of exceptional response in high-grade serous ovarian cancer Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-Ia05 |
0.392 |
|
| 2019 |
Mileshkin LR, Sivakumaran T, Etemadmoghadam D, Tothill R, Fellowes A, Fox SB, Guccione L, Freimund AE, deFazio A, Wilcken N, Gao B, Singh MS, Collins IM, Richardson GE, Steer CB, ... ... Bowtell D, et al. Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years. Journal of Clinical Oncology. 37: 3072-3072. DOI: 10.1200/JCO.2019.37.15_SUPPL.3072 |
0.359 |
|
| 2019 |
Qiao Y, Huang X, Brady S, Bild A, Bowtell D, Johnson W, Marth G. Abstract 4689: Subclone-specific evolution of tumor phenotypes – A framework to study subclone-specific gene expression from a combination of bulk DNA and single cell RNA sequencing data Cancer Research. 79: 4689-4689. DOI: 10.1158/1538-7445.Am2019-4689 |
0.368 |
|
| 2019 |
Aziz D, Lee C, Chin V, Fernandez K, Etemadmoghadam D, Bowtell D, Waring P, Caldon C. Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC) Annals of Oncology. 30: ix86. DOI: 10.1093/annonc/mdz426.029 |
0.347 |
|
| 2019 |
Morrish E, Copeland A, Silke N, Beach J, Christie E, Sandow J, Ebert G, Mackiewicz L, Jarman K, Moujalled D, Pomilio G, Fischer K, Dawson M, Bowtell D, Pellegrini M, et al. TARGETING MULTIDRUG RESISTANCE PROTEIN 1 (MDR1) POTENTIATES SMAC-MIMETIC THERAPY TO KILL LEUKEMIC STEM CELLS AND OVERCOME RESISTANCE IN ACUTE MYELOID LEUKEMIA Experimental Hematology. 76: S79. DOI: 10.1016/J.EXPHEM.2019.06.410 |
0.316 |
|
| 2018 |
Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R, Bowtell D, Waring P. 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes. Gynecologic Oncology. PMID 30209015 DOI: 10.1016/j.ygyno.2018.08.039 |
0.309 |
|
| 2018 |
Delahunty R, Webb P, Chenevix-Trench G, Rutherford A, Cohen P, Young M, Friedlander M, Forrest L, James P, Bowtell D. TRACEBACK: Finding BRCA1 and BRCA2 Mutations in Women with Ovarian Cancer Diagnosed Prior to Changes to Genetic Testing Guidelines Current Oncology. 25. DOI: 10.3747/Co.25.4243 |
0.336 |
|
| 2018 |
Millstein J, Budden T, Anglesio M, Talhouk A, Beeghly-Fadiel A, Berchuck A, Chenevix-Trench G, deFazio A, Fasching PA, Gayther S, García M, Goode EL, Henderson M, Konecny GE, Orsulic S, ... ... Bowtell D, et al. A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer. Journal of Clinical Oncology. 36: 5583-5583. DOI: 10.1200/Jco.2018.36.15_Suppl.5583 |
0.411 |
|
| 2018 |
Kondrashova O, Au-Yeung G, Leas L, Ho G, Lunke S, Alsop K, Scott C, Hamilton A, Ananda S, Freimund A, Quinn M, McNally O, Traficante N, Cowie T, Wakefield M, ... ... Bowtell D, et al. Abstract B35: Australian Ovarian Cancer Assortment Trial–Allocating ovarian cancer patients into clinical trials based on molecular profiling Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Ovca17-B35 |
0.37 |
|
| 2018 |
Moujaber T, Etemadmoghadam D, Mapagu C, Kennedy C, Chiew Y, Kan C, Nevins N, Srirangan S, Fereday S, Traficante N, Bowtell D, Balleine R, Harnett P, deFazio A. Abstract 2584: Mutations in low-grade serous ovarian cancer and response to BRAF and MEK inhibitors Cancer Research. 78: 2584-2584. DOI: 10.1158/1538-7445.Am2018-2584 |
0.417 |
|
| 2017 |
Yang WL, Gentry-Maharaj A, Simmons AR, Ryan A, Fourkala EO, Lu Z, Baggerly KA, Zhao Y, Lu K, Bowtell DDL, Jacobs I, Skates SJ, He WW, Menon U, Bast RC. Elevation of TP53 Autoantibody Prior to CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28637689 DOI: 10.1158/1078-0432.Ccr-17-0284 |
0.363 |
|
| 2016 |
Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, London WB, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc activity signature predicts poor clinical outcomes in Myc-associated cancers. Cancer Research. PMID 27923830 DOI: 10.1158/0008-5472.Can-15-2906 |
0.316 |
|
| 2016 |
Moran S, Martínez-Cardús A, Sayols S, Musulén E, Balañá C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miró M, Matias-Guiu X, Pazo-Cid R, ... ... Bowtell D, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. The Lancet. Oncology. PMID 27575023 DOI: 10.1016/S1470-2045(16)30297-2 |
0.388 |
|
| 2016 |
Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Harnett PR, Bowtell DD, DeFazio A. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecologic Oncology. PMID 27444035 DOI: 10.1016/j.ygyno.2016.06.023 |
0.38 |
|
| 2016 |
Doberstein K, Karst A, Etemadmoghadam D, Jones P, Dunn G, Hahn W, Bowtell D, Drapkin R. Abstract PR05: Identifying potential targets in Cyclin E-amplified tumors. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-Pr05 |
0.425 |
|
| 2016 |
Aziz D, Etemadmoghadam D, Au-Yeung G, Muranyi A, Gresshoff I, Christie M, Hutchinson R, Ferraro D, Stanislaw S, Henricksen L, Tubbs A, Shanmugam K, Bowtell D, Waring P. 298O The clinical significance of deregulated cyclin E1 in high grade serous ovarian cancer (HGSOC) Annals of Oncology. 27. DOI: 10.1093/annonc/mdw585.002 |
0.331 |
|
| 2015 |
Sinha D, Chong L, George J, Schlueter H, Monchgesang S, Mills S, Jason L, Parish CR, Ovarian Cancer Study Group A, Bowtell DD, Kaur P. Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26589433 DOI: 10.1158/1078-0432.Ccr-15-1931 |
0.42 |
|
| 2015 |
Davis SJ, Sheppard KE, Anglesio MS, George J, Traficante N, Fereday S, Intermaggio MP, Menon U, Gentry-Maharaj A, Lubinski J, Gronwald J, Pearce CL, Pike MC, Wu A, Kommoss S, ... ... Bowtell DD, et al. Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics. 14: 1495-503. PMID 25852062 DOI: 10.1158/1535-7163.Mct-15-0039 |
0.316 |
|
| 2015 |
Leong HS, Galletta L, Etemadmoghadam D, George J, Köbel M, Ramus SJ, Bowtell D. Efficient molecular subtype classification of high-grade serous ovarian cancer. The Journal of Pathology. 236: 272-7. PMID 25810134 DOI: 10.1002/path.4536 |
0.345 |
|
| 2015 |
Tothill RW, Shi F, Paiman L, Bedo J, Kowalczyk A, Mileshkin L, Buela E, Klupacs R, Bowtell D, Byron K. Development and validation of a gene expression tumour classifier for cancer of unknown primary. Pathology. 47: 7-12. PMID 25485653 DOI: 10.1097/PAT.0000000000000194 |
0.363 |
|
| 2015 |
Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, de Fazio A, Mitchell G, Fereday S, Bolton KL, Gourley C, ... ... Bowtell D, et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 652-7. PMID 25398451 DOI: 10.1158/1078-0432.Ccr-14-2497 |
0.364 |
|
| 2015 |
Heong V, Topp M, Ananda S, McNally O, Lindeman GJ, Haluska P, Wakefield M, Swisher EM, Tan DS, Ruby H, Bowtell D, Scott CL. Targeting the C5 subclass of high-grade serous ovarian cancer using patient-derived xenografts: Microtubule polymerisation inhibitors. Journal of Clinical Oncology. 33: e22202-e22202. DOI: 10.1200/JCO.2015.33.15_SUPPL.E22202 |
0.391 |
|
| 2015 |
Scott CL, Topp M, Hadley AM, Heong V, Harrell MI, McNally O, Fox SB, Lodhia K, Haluska P, Bowtell D, Swisher EM, Wakefield M. The use of patient-derived xenograft models for prioritizing therapeutic targets. Journal of Clinical Oncology. 33: 5579-5579. DOI: 10.1200/Jco.2015.33.15_Suppl.5579 |
0.341 |
|
| 2015 |
Lheureux S, Ledermann JA, Runswick S, Hodgson DR, Timms K, Lanchbury JS, Kaye SB, Gourley C, Bowtell D, Kohn EC, Scott CL, Matulonis U, Panzarella T, Dougherty BA, Barrett JC, et al. Genomic characterization of long-term responders to olaparib. Journal of Clinical Oncology. 33: 5566-5566. DOI: 10.1200/JCO.2015.33.15_SUPPL.5566 |
0.341 |
|
| 2015 |
Christie E, Hunter T, Bowtell D. Abstract POSTER-CTRL-1203: Circulating TP53 mutations as a biomarker of high-grade serous cancer Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ctrl-1203 |
0.35 |
|
| 2015 |
Curry E, Cheraghchi-Bashi-Astaneh A, Chen M, Cunnea P, Camila DS, Maginn E, Dai Y, Liu E, Wasan H, Mills GB, Bowtell D, Gabra H, Stronach EA. Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A47 |
0.356 |
|
| 2015 |
Au-Yeung G, Lang F, Mitchell C, Jarman K, Lackovic K, Cullinane C, Mileshkin L, Rischin D, Etemadmoghadam D, Bowtell D. 1PD A high throughput compound screen identifies potential combinations to overcome resistance to Cdk2 inhibitors in Cyclin E1 amplified high grade serous ovarian cancer Annals of Oncology. 26: ix1. DOI: 10.1093/annonc/mdv517.01 |
0.303 |
|
| 2015 |
Kondrashova O, Lunke S, Mileshkin L, Alsop K, Scott C, Hamilton A, Ananda S, Quinn M, Bowtell D, McNally O, Cowie T, Wakefield M, Hsu A, Taylor G, Waring P. 2773 ALLOCATE: sorting ovarian cancer patients into treatment categories based on genetic characteristics of their tumours European Journal of Cancer. 51: S555. DOI: 10.1016/S0959-8049(16)31539-8 |
0.354 |
|
| 2014 |
Wasan H, Paul J, Nicolson MC, Evans TR, McMahon L, Morris A, McCartney E, Bridgewater C, Bowtell D, Erlander M, Oien KA. 1139PDCLINICAL OUTCOMES FROM THE UK CUP-ONE STUDY: A MULTI-CENTRE TRIAL TO ASSESS THE EFFICACY OF EPIRUBICIN, CISPLATIN AND CAPECITABINE (ECX) IN CARCINOMAS OF UNKNOWN PRIMARY (CUP) WITH PROSPECTIVE VALIDATION OF MOLECULAR CLASSIFIERS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv397. PMID 28171218 DOI: 10.1093/annonc/mdu345.8 |
0.309 |
|
| 2014 |
Etemadmoghadam D, Bowtell D. AKT1 gene amplification as a biomarker of treatment response in ovarian cancer: mounting evidence of a therapeutic target. Gynecologic Oncology. 135: 409-10. PMID 25498304 DOI: 10.1016/j.ygyno.2014.11.007 |
0.38 |
|
| 2014 |
Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. The Journal of Clinical Investigation. 124: 4614-28. PMID 25202979 DOI: 10.1172/Jci74778 |
0.342 |
|
| 2014 |
Gao B, Russell A, Beesley J, Chen XQ, Healey S, Henderson M, Wong M, Emmanuel C, Galletta L, Johnatty SE, Bowtell D, Haber M, Norris M, Harnett P, et al. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports. 4: 4669. PMID 24810093 DOI: 10.1038/srep04669 |
0.401 |
|
| 2014 |
Cooke SL, Shlien A, Marshall J, Pipinikas CP, Martincorena I, Tubio JM, Li Y, Menzies A, Mudie L, Ramakrishna M, Yates L, Davies H, Bolli N, Bignell GR, Tarpey PS, ... ... Bowtell D, et al. Processed pseudogenes acquired somatically during cancer development. Nature Communications. 5: 3644. PMID 24714652 DOI: 10.1038/ncomms4644 |
0.419 |
|
| 2014 |
Sjoquist KM, Friedlander M, Mileshkin LR, Quinn M, Goh JC, Shannon CM, Bowtell D, Plebanski M, Yip S, Carlton K, Gillies K, Martyn J, Gebski V, Anzgog NC. The REZOLVE phase II trial to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced, chemotherapy-resistant ovarian cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5627 |
0.312 |
|
| 2014 |
Hirst C, Parry D, Alsop K, deFazio A, Fereday S, Mitchell G, Bowtell D, Emmanuel C. Survival in patients with BRCA mutation-positive platinum-sensitive recurrent ovarian cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E16519 |
0.389 |
|
| 2014 |
Mileshkin LR, Byron K, Tothill R, Shi F, Paiman L, Bedo J, Kowalczyk A, Buela E, Klupacs R, Bowtell D. Development of a histology-guided gene expression tumor classifier for cancer of unknown primary (CUP). Journal of Clinical Oncology. 32: 11108-11108. DOI: 10.1200/Jco.2014.32.15_Suppl.11108 |
0.334 |
|
| 2014 |
Dobrovic A, Mikeska T, Alsop K, Candiloro I, George J, Mitchell G, Bowtell D. Abstract 290: Constitutional BRCA1 methylation is a major predisposition factor for high-grade serous ovarian cancer Cancer Research. 74: 290-290. DOI: 10.1158/1538-7445.Am2014-290 |
0.373 |
|
| 2014 |
Heong V, Topp M, Rutkowski R, Ananda S, Wong S, Swisher E, Lindeman G, Haber M, Norris MD, Haluska P, Wakefield M, Bowtell D, Scott CL. OP0024 Use of novel patient-derived xenografts and molecular subtyping to improve precision medicine in high-grade serous ovarian cancer European Journal of Cancer. 50. DOI: 10.1016/J.Ejca.2014.03.042 |
0.395 |
|
| 2013 |
Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Fazil L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 23: 332-46. PMID 23518348 DOI: 10.1016/j.ccr.2013.02.016 |
0.335 |
|
| 2013 |
Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D, Obermair A. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecologic Oncology. 129: 467-71. PMID 23500084 DOI: 10.1016/j.ygyno.2013.03.001 |
0.301 |
|
| 2013 |
Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, ... ... Bowtell DD, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of Clinical Investigation. 123: 517-25. PMID 23257362 DOI: 10.1172/Jci65833 |
0.554 |
|
| 2013 |
Qi J, Tripathi M, Sahgal N, Fazil L, Ettinger S, Placzek WJ, Claps G, Chung LWK, Bowtell D, Gleave M, Bhowmick N, Ronai Z. Abstract 5456: The E3 ubiquitin ligase Siah2 regulates the androgen receptor activity and contributes to castration-resistant prostate cancer. Cancer Research. 73: 5456-5456. DOI: 10.1158/1538-7445.Am2013-5456 |
0.356 |
|
| 2013 |
Campbell I, Hunter S, Mathew W, Antill Y, Bae S, Ananda S, Topp M, Lipton L, Liauw W, Jobling T, Boussioutas A, Christie M, Allan P, Friedlander M, Fox S, ... ... Bowtell D, et al. Abstract A3: Mucinous ovarian tumors: Are they all the same? Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A3 |
0.425 |
|
| 2012 |
Sawyer S, Mitchell G, McKinley J, Chenevix-Trench G, Beesley J, Chen XQ, Bowtell D, Trainer AH, Harris M, Lindeman GJ, James PA. A role for common genomic variants in the assessment of familial breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4330-6. PMID 23109704 DOI: 10.1200/JCO.2012.41.7469 |
0.324 |
|
| 2012 |
Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2654-63. PMID 22711857 DOI: 10.1200/JCO.2011.39.8545 |
0.372 |
|
| 2012 |
Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Research. 72: 2701-4. PMID 22593197 DOI: 10.1158/0008-5472.CAN-11-3911 |
0.315 |
|
| 2012 |
Topp M, Hartley L, Cook M, Etemadmoghadam D, Galleta L, Pyman J, McNally O, Haluska P, Swisher EM, Kaufmann SH, Wakefield M, Bowtell D, Scott CL. Targeting therapy based on preclinical analysis of clinical, molecular, and functional characteristics of individual high-grade serous ovarian cancers. Journal of Clinical Oncology. 30: 5073-5073. DOI: 10.1200/Jco.2012.30.15_Suppl.5073 |
0.341 |
|
| 2012 |
Traficante N, Fereday S, Galletta L, Hung J, Giles D, Alsop K, Hendley J, Iuga A, Chenevix-Trench G, Green A, Webb P, DeFazio A, Bowtell D. The Australian Ovarian Cancer Study Hereditary Cancer in Clinical Practice. 10: 1-2. DOI: 10.1186/1897-4287-10-S2-A94 |
0.368 |
|
| 2012 |
Hung J, Fereday S, Harnett P, Giles D, Gao B, Traficante N, Chenevix-Trench G, Green A, Webb P, Bowtell D, DeFazio A. Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study Hereditary Cancer in Clinical Practice. 10: 1-1. DOI: 10.1186/1897-4287-10-S2-A80 |
0.37 |
|
| 2012 |
Topp M, Hartley L, Cook M, Etemadmoghadam D, Galleta L, Moss P, Pyman J, McNally O, Haluska P, Swisher E, Kaufmann S, Kerr J, Wakefield M, Bowtell D, Scott CL. Abstract 3276: A novel in vivo xenograft mouse model of human high-grade serous ovarian cancer, with clinical, molecular and functional annotation relevant for pre-clinical analysis Cancer Research. 72: 3276-3276. DOI: 10.1158/1538-7445.Am2012-3276 |
0.345 |
|
| 2012 |
Byron K, Paiman L, Tothill R, Beula E, Shi F, Kowalczyk A, Klupacs R, Bowtell D. Development of a gene expression based assay to determine the origin of metastatic carcinomas of unknown primary Pathology. 44. DOI: 10.1016/S0031-3025(16)32786-6 |
0.331 |
|
| 2011 |
Alsop K, Fereday S, Meldrum C, deFazio A, Webb P, Birrer MJ, Friedlander M, Fox SB, Bowtell D, Mitchell G. Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5026. PMID 28023739 DOI: 10.1200/jco.2011.29.15_suppl.5026 |
0.407 |
|
| 2011 |
Wasan HS, Evans TR, Nicolson M, Bowtell D, Oien K, Erlander MG, Paul J, Maclean M, McMahon L. A phase II study of ECX in patients with carcinoma of unknown primary (CUP): Prospective evaluation of molecular classifiers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e21065. PMID 28022206 DOI: 10.1200/jco.2011.29.15_suppl.e21065 |
0.318 |
|
| 2011 |
Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. Plos One. 6: e21121. PMID 21754983 DOI: 10.1371/Journal.Pone.0021121 |
0.429 |
|
| 2011 |
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, ... ... Bowtell D, et al. Integrated genomic analyses of ovarian carcinoma Nature. 474: 609-615. PMID 21720365 DOI: 10.1038/Nature10166 |
0.444 |
|
| 2011 |
Helland Ã…, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, ... ... Bowtell DD, et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. Plos One. 6: e18064. PMID 21533284 DOI: 10.1371/Journal.Pone.0018064 |
0.318 |
|
| 2011 |
Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, et al. Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. Plos One. 6: e17617. PMID 21423607 DOI: 10.1371/journal.pone.0017617 |
0.337 |
|
| 2011 |
Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, ... ... Bowtell DD, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 2538-48. PMID 21343371 DOI: 10.1158/1078-0432.CCR-10-3314 |
0.302 |
|
| 2011 |
Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB, Bowtell DD, Harvey KF. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene. 30: 2810-22. PMID 21317925 DOI: 10.1038/onc.2011.8 |
0.351 |
|
| 2011 |
Ahmed AA, Bast RC, Bowtell D, Goldsmith J. Abstract 4822: Nonsense mediated decay defines deleterious TP53 mutations and tumor aggressiveness in ovarian cancer Cancer Research. 71: 4822-4822. DOI: 10.1158/1538-7445.Am2011-4822 |
0.42 |
|
| 2011 |
Henderson MJ, Hedditch EL, Russell AJ, deFazio A, Emmanuel C, George J, Chenevix-Trench G, Bowtell D, Norris MD, Haber M. Abstract 1660: Cholesterol efflux transporter gene expression predicts clinical outcome in serous ovarian cancer Cancer Research. 71: 1660-1660. DOI: 10.1158/1538-7445.Am2011-1660 |
0.404 |
|
| 2010 |
Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nature Reviews. Cancer. 10: 803-8. PMID 20944665 DOI: 10.1038/nrc2946 |
0.302 |
|
| 2010 |
Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, ... Bowtell D, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 18: 109-21. PMID 20708153 DOI: 10.1016/J.Ccr.2010.06.018 |
0.402 |
|
| 2010 |
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, ... ... Bowtell DD, et al. International network of cancer genome projects. Nature. 464: 993-8. PMID 20393554 DOI: 10.1038/Nature08987 |
0.546 |
|
| 2010 |
Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. The Journal of Pathology. 221: 49-56. PMID 20229506 DOI: 10.1002/path.2696 |
0.355 |
|
| 2009 |
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB, Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, Cheng LL, Lee J, Rha SY, Chung HC, Ganesan K, ... ... Bowtell D, et al. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. Plos Genetics. 5: e1000676. PMID 19798449 DOI: 10.1371/journal.pgen.1000676 |
0.396 |
|
| 2009 |
Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 16: 115-25. PMID 19647222 DOI: 10.1016/J.Ccr.2009.06.006 |
0.353 |
|
| 2009 |
Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, ... ... Bowtell D, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1417-27. PMID 19193619 DOI: 10.1158/1078-0432.Ccr-08-1564 |
0.424 |
|
| 2008 |
Qi J, Nakayama K, Gaitonde S, Goydos JS, Krajewski S, Eroshkin A, Bar-Sagi D, Bowtell D, Ronai Z. The ubiquitin ligase Siah2 regulates tumorigenesis and metastasis by HIF-dependent and -independent pathways. Proceedings of the National Academy of Sciences of the United States of America. 105: 16713-8. PMID 18946040 DOI: 10.1073/Pnas.0804063105 |
0.308 |
|
| 2008 |
Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, ... ... Bowtell DD, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5198-208. PMID 18698038 DOI: 10.1158/1078-0432.Ccr-08-0196 |
0.308 |
|
| 2006 |
Millward MJ, House C, Bowtell D, Webster L, Olver IN, Gore M, Copeman M, Lynch K, Yap A, Wang Y, Cohen PS, Zalcberg J. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. British Journal of Cancer. 95: 829-34. PMID 16969355 DOI: 10.1038/sj.bjc.6603331 |
0.306 |
|
| 2006 |
OzdaÄŸ H, Teschendorff AE, Ahmed AA, Hyland SJ, Blenkiron C, Bobrow L, Veerakumarasivam A, Burtt G, Subkhankulova T, Arends MJ, Collins VP, Bowtell D, Kouzarides T, Brenton JD, Caldas C. Differential expression of selected histone modifier genes in human solid cancers. Bmc Genomics. 7: 90. PMID 16638127 DOI: 10.1186/1471-2164-7-90 |
0.372 |
|
| 2006 |
Aggarwal A, Guo DL, Hoshida Y, Yuen ST, Chu KM, So S, Boussioutas A, Chen X, Bowtell D, Aburatani H, Leung SY, Tan P. Topological and functional discovery in a gene coexpression meta-network of gastric cancer. Cancer Research. 66: 232-41. PMID 16397236 DOI: 10.1158/0008-5472.Can-05-2232 |
0.368 |
|
| 2005 |
du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: viii7-viii12. PMID 16239238 DOI: 10.1093/annonc/mdi961 |
0.372 |
|
| 2005 |
Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, et al. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: viii36-viii38. PMID 16239235 DOI: 10.1093/annonc/mdi965 |
0.356 |
|
| 2003 |
Boussioutas A, Van Laar R, Desmond P, Bowtell D. Prediction of disease-free survival in gastric cancer using gene expression data Gastroenterology. 124: A554-A555. DOI: 10.1016/S0016-5085(03)82807-X |
0.348 |
|
| 2002 |
Kong CF, Bowtell D. Genomewide gene expression analysis using cDNA microarrays Methods in Molecular Medicine. 68: 195-204. PMID 11901503 DOI: 10.1385/1-59259-135-3:195 |
0.312 |
|
| 1995 |
Sakaue M, Bowtell D, Kasuga M. A dominant-negative mutant of mSOS1 inhibits insulin-induced Ras activation and reveals Ras-dependent and -independent insulin signaling pathways Molecular and Cellular Biology. 15: 379-388. PMID 7799946 DOI: 10.1128/Mcb.15.1.379 |
0.3 |
|
| 1994 |
Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway Embo Journal. 13: 764-773. PMID 8112292 DOI: 10.1002/J.1460-2075.1994.Tb06319.X |
0.315 |
|
| 1994 |
Lioubin MN, Myles GM, Carlberg K, Bowtell D, Rohrschneider LR. Shc, Grb2, Sos1, and a 150-kilodalton tyrosine-phosphorylated protein form complexes with Fms in hematopoietic cells Molecular and Cellular Biology. 14: 5682-5691. PMID 7520523 DOI: 10.1128/Mcb.14.9.5682 |
0.304 |
|
| 1993 |
Simon M, Dodson G, Rubin G, Olivier J, Egan S, Giddings B, Brooks M, Buday L, Sizeland A, Weinberg R, Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D, et al. Tyrosine kinases to Ras Trends in Cell Biology. 3: 228. DOI: 10.1016/0962-8924(93)90117-J |
0.461 |
|
| 1992 |
Bowtell D, Fu P, Simon M, Senior P. Identification of murine homologues of the Drosophila son of sevenless gene: Potential activators of ras Proceedings of the National Academy of Sciences of the United States of America. 89: 6511-6515. PMID 1631150 DOI: 10.1073/pnas.89.14.6511 |
0.51 |
|
| 1991 |
Simon MA, Bowtell DD, Dodson GS, Laverty TR, Rubin GM. Ras1 and a putative guanine nucleotide exchange factor perform crucial steps in signaling by the sevenless protein tyrosine kinase. Cell. 67: 701-16. PMID 1934068 DOI: 10.1016/0092-8674(91)90065-7 |
0.58 |
|
| 1991 |
Bowtell DD, Lila T, Michael WM, Hackett D, Rubin GM. Analysis of the enhancer element that controls expression of sevenless in the developing Drosophila eye. Proceedings of the National Academy of Sciences of the United States of America. 88: 6853-7. PMID 1907377 DOI: 10.1073/pnas.88.15.6853 |
0.49 |
|
| 1990 |
Michael WM, Bowtell DD, Rubin GM. Comparison of the sevenless genes of Drosophila virilis and Drosophila melanogaster. Proceedings of the National Academy of Sciences of the United States of America. 87: 5351-3. PMID 2115169 DOI: 10.1073/pnas.87.14.5351 |
0.475 |
|
| 1989 |
Bowtell DD, Simon MA, Rubin GM. Ommatidia in the developing Drosophila eye require and can respond to sevenless for only a restricted period. Cell. 56: 931-6. PMID 2924353 DOI: 10.1016/0092-8674(89)90626-0 |
0.578 |
|
| 1989 |
Simon MA, Bowtell DD, Rubin GM. Structure and activity of the sevenless protein: a protein tyrosine kinase receptor required for photoreceptor development in Drosophila. Proceedings of the National Academy of Sciences of the United States of America. 86: 8333-7. PMID 2682647 DOI: 10.1073/Pnas.86.21.8333 |
0.572 |
|
| 1989 |
Bowtell DD, Kimmel BE, Simon MA, Rubin GM. Regulation of the complex pattern of sevenless expression in the developing Drosophila eye. Proceedings of the National Academy of Sciences of the United States of America. 86: 6245-9. PMID 2503829 DOI: 10.1073/Pnas.86.16.6245 |
0.696 |
|
| 1988 |
Bowtell DD, Simon MA, Rubin GM. Nucleotide sequence and structure of the sevenless gene of Drosophila melanogaster. Genes & Development. 2: 620-34. PMID 3138161 DOI: 10.1101/Gad.2.6.620 |
0.569 |
|
| 1987 |
Tomlinson A, Bowtell DD, Hafen E, Rubin GM. Localization of the sevenless protein, a putative receptor for positional information, in the eye imaginal disc of Drosophila. Cell. 51: 143-50. PMID 3115593 DOI: 10.1016/0092-8674(87)90019-5 |
0.666 |
|
| Show low-probability matches. |